Pfizer Acquires Pyxis Oncology for $1.1 Billion
Ticker: PYXS · Form: 8-K · Filed: Feb 26, 2025 · CIK: 1782223
| Field | Detail |
|---|---|
| Company | Pyxis Oncology, Inc. (PYXS) |
| Form Type | 8-K |
| Filed Date | Feb 26, 2025 |
| Risk Level | medium |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, merger, pharma
TL;DR
Pfizer buying Pyxis Oncology for $1.1B cash, deal expected Q2 2025.
AI Summary
Pyxis Oncology, Inc. announced on February 26, 2025, that it has entered into a definitive agreement to be acquired by Pfizer Inc. for $9.00 per share in cash, representing a total equity value of approximately $1.1 billion. This transaction is expected to close in the second quarter of 2025, subject to customary closing conditions.
Why It Matters
This acquisition by a major pharmaceutical company like Pfizer could significantly impact the development and accessibility of Pyxis Oncology's drug candidates, potentially accelerating their path to market.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, which introduces a degree of uncertainty until the deal is finalized.
Key Numbers
- $1.1B — Total Equity Value (The total value of Pyxis Oncology being acquired by Pfizer.)
- $9.00 — Per Share Price (The cash amount each Pyxis Oncology shareholder will receive.)
Key Players & Entities
- Pyxis Oncology, Inc. (company) — Registrant
- Pfizer Inc. (company) — Acquiring company
- $9.00 (dollar_amount) — Per share acquisition price
- $1.1 billion (dollar_amount) — Total equity value of the acquisition
- February 26, 2025 (date) — Date of the report and earliest event
- second quarter of 2025 (date) — Expected closing period for the acquisition
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing reports on the material event of Pyxis Oncology, Inc. entering into a definitive agreement to be acquired by Pfizer Inc.
What is the acquisition price per share for Pyxis Oncology?
Pyxis Oncology, Inc. is being acquired by Pfizer Inc. for $9.00 per share in cash.
What is the total estimated equity value of the acquisition?
The acquisition of Pyxis Oncology, Inc. by Pfizer Inc. has an estimated total equity value of approximately $1.1 billion.
When is the acquisition expected to be completed?
The transaction between Pyxis Oncology, Inc. and Pfizer Inc. is expected to close in the second quarter of 2025.
Are there any specific conditions mentioned for the closing of the acquisition?
Yes, the acquisition is subject to customary closing conditions.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 26, 2025 regarding Pyxis Oncology, Inc. (PYXS).